Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
Eli Lilly will assess its JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.
Sinovac Biotech announced positive early data from a Phase I/II clinical trial of its COVID-19 vaccine, CoronaVac. The vaccine showed both favorable immunogenicity and safety.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Although clinical trials are often performed throughout different parts of the world, often their demographic makeup—the gender, age and race of participants—has a certain kind of uniformity.
Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.
Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020, speaking Thursday in a virtual session.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
The primary endpoint of the trial will be prevention of symptomatic COVID-19 disease, with key secondary endpoints including prevention of severe COVID-19, defined as hospitalization, and prevention of infection by SARS-CoV-2.
Results from the Phase III JADE TEEN study of abrocitinib in teen patients, ages 12 to 18, who have moderate to severe atopic dermatitis and were on background topical therapy, showed improvements in skin clearance, disease extent and a reduction in severity.
PRESS RELEASES